10:38 AM EST - Medicenna Therapeutics Corp. : Today reported financial results for the three months ended June 30, 2026. The Company reported total operating costs of $5.4 million, compared with total operating costs of $5.5 million for the three months ended June 30, 2025. Net loss for the three months ended June 30, 2026, was $5.1 million ($0.06 loss per share), compared to a net loss of $4.9 million ($0.06 loss per share) for the three months ended June 30, 2025. Medicenna Therapeutics Corp.
shares T.MDNA are trading up $0.02 at $0.42.
